Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 3,250 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 3,250 shares of the company’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $21.59, for a total transaction of $70,167.50. Following the sale, the chief financial officer now directly owns 13,000 shares of the company’s stock, valued at $280,670. The trade was a 20.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.04, for a total transaction of $25,040.00.
• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.51, for a total transaction of $20,259.00.
• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.15, for a total transaction of $74,202.50.
• On Wednesday, November 27th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.89, for a total value of $130,672.50.

Enliven Therapeutics Stock Up 2.8 %

NASDAQ:ELVN opened at $21.86 on Friday. The business’s 50-day simple moving average is $23.04 and its two-hundred day simple moving average is $24.27. Enliven Therapeutics, Inc. has a 52 week low of $10.90 and a 52 week high of $30.03. The stock has a market cap of $1.07 billion, a PE ratio of -11.51 and a beta of 1.04.

Wall Street Analysts Forecast Growth

ELVN has been the subject of a number of analyst reports. Robert W. Baird upped their price target on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. BTIG Research initiated coverage on shares of Enliven Therapeutics in a report on Friday, December 13th. They issued a “buy” rating and a $42.00 target price for the company. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $38.25.

Institutional Trading of Enliven Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. FMR LLC boosted its stake in Enliven Therapeutics by 10.6% in the 3rd quarter. FMR LLC now owns 6,296,179 shares of the company’s stock worth $160,804,000 after purchasing an additional 601,611 shares during the period. Lord Abbett & CO. LLC purchased a new position in shares of Enliven Therapeutics in the third quarter worth $8,199,000. Janus Henderson Group PLC boosted its position in shares of Enliven Therapeutics by 43.0% during the third quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company’s stock worth $26,611,000 after acquiring an additional 313,019 shares during the last quarter. Ally Bridge Group NY LLC purchased a new position in Enliven Therapeutics during the third quarter valued at $5,998,000. Finally, Marshall Wace LLP bought a new stake in Enliven Therapeutics in the 2nd quarter valued at $4,489,000. Institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.